Literature DB >> 23063134

Systemic oxidative stress, as measured by urinary allantoin and F(2)-isoprostanes, is not increased in Down syndrome.

Adviye A Tolun1, Peter M Scarbrough, Haoyue Zhang, Jane-Ann McKillop, Frances Wang, Priya S Kishnani, David S Millington, Sarah P Young, Dora Il'yasova.   

Abstract

PURPOSE: Oxidative stress has been implicated in Down syndrome (DS) pathology. This study compares DS individuals and controls on their urinary levels of allantoin and 2,3-dinor-iPF2α-III; these biomarkers have been previously validated in a clinical model of oxidative stress.
METHODS: Urine samples were collected from 48 individuals with DS and 130 controls. Biomarkers were assayed by ultraperformance liquid chromatography-tandem mass spectrometry, normalized by urinary creatinine concentration.
RESULTS: After adjusting for age and gender, mean allantoin levels were lower among DS individuals versus controls (P = .04). The adjusted mean levels of 2,3-dinor-iPF2α-III were similar in DS individuals and controls (P = .7).
CONCLUSIONS: Our results do not support the hypothesis that DS individuals have chronic systemic oxidative stress.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23063134      PMCID: PMC3508197          DOI: 10.1016/j.annepidem.2012.09.005

Source DB:  PubMed          Journal:  Ann Epidemiol        ISSN: 1047-2797            Impact factor:   3.797


  25 in total

Review 1.  Nutritional supplementation in Down syndrome: theoretical considerations and current status.

Authors:  C Ani; S Grantham-McGregor; D Muller
Journal:  Dev Med Child Neurol       Date:  2000-03       Impact factor: 5.449

2.  Down's syndrome is associated with increased 8,12-iso-iPF2alpha-VI levels: evidence for enhanced lipid peroxidation in vivo.

Authors:  D Praticò; L Iuliano; G Amerio; L X Tang; J Rokach; G Sabatino; F Violi
Journal:  Ann Neurol       Date:  2000-11       Impact factor: 10.422

3.  Urinary F2-isoprostanes, obesity, and weight gain in the IRAS cohort.

Authors:  Dora Il'yasova; Frances Wang; Ivan Spasojevic; Karel Base; Ralph B D'Agostino; Lynne E Wagenknecht
Journal:  Obesity (Silver Spring)       Date:  2011-09-29       Impact factor: 5.002

4.  Urinary biomarkers of oxidative status in a clinical model of oxidative assault.

Authors:  Dora Il'yasova; Ivan Spasojevic; Frances Wang; Adviye A Tolun; Karel Base; Sarah P Young; P Kelly Marcom; Jeffrey Marks; Gabriel Mixon; Richard DiGiulio; David S Millington
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2010-05-25       Impact factor: 4.254

5.  Allantoin in human urine quantified by ultra-performance liquid chromatography-tandem mass spectrometry.

Authors:  Adviye A Tolun; Haoyue Zhang; Dora Il'yasova; Judit Sztáray; Sarah P Young; David S Millington
Journal:  Anal Biochem       Date:  2010-03-31       Impact factor: 3.365

6.  Evaluation of urinary biomarkers of oxidative/nitrosative stress in adolescents and adults with Down syndrome.

Authors:  Carlos Campos; Rodrigo Guzmán; Encarnación López-Fernández; Angela Casado
Journal:  Biochim Biophys Acta       Date:  2011-04-05

7.  Quantification of the oxidative damage biomarker 2,3-dinor-8-isoprostaglandin-F(2alpha) in human urine using liquid chromatography-tandem mass spectrometry.

Authors:  Haoyue Zhang; Dora Il'yasova; Judit Sztaray; Sarah P Young; Frances Wang; David S Millington
Journal:  Anal Biochem       Date:  2009-12-22       Impact factor: 3.365

8.  Evaluation of urinary biomarkers of oxidative/nitrosative stress in children with Down syndrome.

Authors:  Carlos Campos; Rodrigo Guzmán; Encarnación López-Fernández; Angela Casado
Journal:  Life Sci       Date:  2011-08-17       Impact factor: 5.037

9.  Oxidative stress and cognitive ability in adults with Down syndrome.

Authors:  Andre Strydom; Mark J Dickinson; Simadevi Shende; Domenico Pratico; Zuzana Walker
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2008-10-25       Impact factor: 5.067

10.  Long-term monitoring of patients with infantile-onset Pompe disease on enzyme replacement therapy using a urinary glucose tetrasaccharide biomarker.

Authors:  Sarah P Young; Haoyue Zhang; Deyanira Corzo; Beth L Thurberg; Deeksha Bali; Priya S Kishnani; David S Millington
Journal:  Genet Med       Date:  2009-07       Impact factor: 8.822

View more
  4 in total

Review 1.  Disturbance of redox homeostasis in Down Syndrome: Role of iron dysmetabolism.

Authors:  Eugenio Barone; Andrea Arena; Elizabeth Head; D Allan Butterfield; Marzia Perluigi
Journal:  Free Radic Biol Med       Date:  2017-07-10       Impact factor: 7.376

Review 2.  Redox proteomics analysis to decipher the neurobiology of Alzheimer-like neurodegeneration: overlaps in Down's syndrome and Alzheimer's disease brain.

Authors:  D Allan Butterfield; Fabio Di Domenico; Aaron M Swomley; Elizabeth Head; Marzia Perluigi
Journal:  Biochem J       Date:  2014-10-15       Impact factor: 3.857

3.  Memory decline in Down syndrome and its relationship to iPF2alpha, a urinary marker of oxidative stress.

Authors:  Panagiotis Zis; Patrick McHugh; Andrew McQuillin; Domenico Praticò; Mark Dickinson; Sima Shende; Zuzana Walker; Andre Strydom
Journal:  PLoS One       Date:  2014-06-05       Impact factor: 3.240

4.  African Ancestry Gradient Is Associated with Lower Systemic F2-Isoprostane Levels.

Authors:  Francis Annor; Michael Goodman; Bharat Thyagarajan; Ike Okosun; Ayo Doumatey; Barbara A Gower; Dora Il'yasova
Journal:  Oxid Med Cell Longev       Date:  2017-01-31       Impact factor: 6.543

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.